best glp-1 drugs for weight loss Comparing Ozempic, Wegovy and Other Researchers move closer to matching

(September 2022)

27 While we await outcomes of the FOCUS trial, which is dedicated to assessing the effects of semaglutide on eye health, patients using subcutaneous semaglutide should be counselled about the increased risk of retinopathy

Anna Lembke, a Stanford University addiction medicine specialist

While the recent phase 3 trial for orforglipron was specifically for type 2 diabetes and not weight loss, the study found that patients who took the drug lost considerable weight

Katsila T., Spyroulias G

A phase 2 study randomized participants to bremelanotide 1.25 mg daily and tirzepatide 2.5 mg weekly, bremelanotide alone, tirzepatide alone, and placebo, all for 4 weeks, after a 4-week run in period with tirzepatide 2.5 mg weekly (128)